• 中国精品科技期刊
  • 《中文核心期刊要目总览》收录期刊
  • RCCSE 中国核心期刊(5/114,A+)
  • Scopus收录期刊
  • 美国《化学文摘》(CA)收录期刊
  • WHO 西太平洋地区医学索引(WPRIM)收录期刊
  • 《中国科学引文数据库(CSCD)》核心库期刊 (C)
  • 中国科技核心期刊
  • 中国科技论文统计源期刊
  • 《日本科学技术振兴机构数据库(中国)》(JSTChina)收录期刊
  • 美国《乌利希期刊指南》(UIrichsweb)收录期刊
  • 中华预防医学会系列杂志优秀期刊(2019年)

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

我国消除疟疾后再输入风险评估研究进展

刘巧 刘珏

刘巧, 刘珏. 我国消除疟疾后再输入风险评估研究进展[J]. 中华疾病控制杂志, 2024, 28(1): 92-95. doi: 10.16462/j.cnki.zhjbkz.2024.01.014
引用本文: 刘巧, 刘珏. 我国消除疟疾后再输入风险评估研究进展[J]. 中华疾病控制杂志, 2024, 28(1): 92-95. doi: 10.16462/j.cnki.zhjbkz.2024.01.014
LIU Qiao, LIU Jue. Advances in risk assessment of importation after elimination of malaria in China[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2024, 28(1): 92-95. doi: 10.16462/j.cnki.zhjbkz.2024.01.014
Citation: LIU Qiao, LIU Jue. Advances in risk assessment of importation after elimination of malaria in China[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2024, 28(1): 92-95. doi: 10.16462/j.cnki.zhjbkz.2024.01.014

我国消除疟疾后再输入风险评估研究进展

doi: 10.16462/j.cnki.zhjbkz.2024.01.014
基金项目: 

国家自然科学基金 72122001

国家自然科学基金 72211540398

科技部对发展中国家科技援助 KY202101004

详细信息
    通讯作者:

    刘珏,E-mail: jueliu@bjmu.edu.cn

  • 中图分类号: R183.5

Advances in risk assessment of importation after elimination of malaria in China

Funds: 

National Natural Science Foundation of China 72122001

National Natural Science Foundation of China 72211540398

National Science and Technology Project on Development Assistance for Technology, Developing China-ASEAN Public Health Research and Development Collaborating Center KY202101004

More Information
  • 摘要: 中国于2021年被WHO认证成功消除疟疾,但仍面临境外疟疾的输入风险。现阶段中国疟疾防控应侧重预防输入和输入后再传播。本研究就目前中国防疟疾输入面临的主要问题,以及对已经建立的消除后阶段疟疾输入风险评估指标体系进行综述,为中国未来疟疾防控提出建议。
  • [1] World Health Organization. WHO fact sheets: malaria[EB/OL]. (2022-12-08)[2023-01-01]. https://www.who.int/news-room/fact-sheets/detail/malaria.
    [2] Zhang QQ, Liu Y, Hu YB, et al. The "1-3-7" approach to malaria surveillance and response - Henan Province, China, 2012-2018[J]. China CDC Wkly, 2020, 2(17): 289-292. DOI: 10.46234/ccdcw2020.074.
    [3] Andriopoulos P, Economopoulou A, Spanakos G, et al. A local outbreak of autochthonous Plasmodium vivax malaria in Laconia, Greece: a re-emerging infection in the southern borders of Europe?[J]. Int J Infect Dis, 2013, 17(2): e125-e128. DOI: 10.1016/j.ijid.2012.09.009.
    [4] Li ZJ, Yang YC, Xiao N, et al. Malaria imported from Ghana by returning gold miners, China, 2013[J]. Emerg Infect Dis, 2015, 21(5): 864-867. DOI: 10.3201/2105.141712.
    [5] Ericsson CD, Hatz C, Leder K, et al. Illness in travelers visiting friends and relatives: a review of the GeoSentinel surveillance network[J]. Clin Infect Dis, 2006, 43(9): 1185-1193. DOI: 10.1086/507893.
    [6] Fried M, Duffy PE. Malaria during pregnancy[J]. Cold Spring Harb Perspect Med, 2017, 7(6): a025551. DOI: 10.1101/cshperspect.a025551.
    [7] Arisco NJ, Peterka C, Castro MC. Cross-border malaria in northern Brazil[J]. Malar J, 2021, 20(1): 1-13. DOI: 10.1186/s12936-021-03668-4.
    [8] Wangdi K, Gatton ML, Kelly GC, et al. Cross-border malaria: a major obstacle for malaria elimination[J]. Adv Parasitol, 2015, 89: 79-107. DOI: 10.1016/bs.apar.2015.04.002.
    [9] Bousema T, Okell L, Felger I, et al. Asymptomatic malaria infections: detectability, transmissibility and public health relevance[J]. Nat Rev Microbiol, 2014, 12(12): 833-840. DOI: 10.1038/nrmicro3364.
    [10] Lee RA, Puig H, Nguyen PQ, et al. Ultrasensitive CRISPR-based diagnostic for field-applicable detection of Plasmodium species in symptomatic and asymptomatic malaria[J]. Proc Natl Acad Sci USA, 2020, 117(41): 25722-25731. DOI: 10.1073/pnas.2010196117.
    [11] Huang F, Takala-Harrison S, Liu H, et al. Prevalence of clinical and subclinical Plasmodium falciparum and Plasmodium vivax malaria in two remote rural communities on the Myanmar-China border[J]. Am J Trop Med Hyg, 2017, 97(5): 1524-1531. DOI: 10.4269/ajtmh.17-0167.
    [12] Baird JK. 8-aminoquinoline therapy for latent malaria[J]. Clin Microbiol Rev, 2019, 32(4): e00011-e00019. DOI: 10.1128/CMR.00011-19.
    [13] Marteau A, Ouedraogo E, ven der Meersch G, et al. Severe long-delayed malaria caused by plasmodium malariae in an elderly French patient[J]. Malar J, 2021, 20(1): 337. DOI: 10.1186/s12936-021-03870-4.
    [14] ven der Berg H. Global status of DDT and its alternatives for use in vector control to prevent disease[J]. Environ Health Perspect, 2009, 117(11): 1656-1663. DOI: 10.1289/ehp.0900785.
    [15] Adjuik M, Babiker A, Garner P, et al. Artesunate combinations for treatment of malaria: meta-analysis[J]. Lancet, 2004, 363(9402): 9-17. DOI: 10.1016/s0140-6736(03)15162-8.
    [16] Balikagala B, Fukuda N, Ikeda M, et al. Evidence of artemisinin-resistant malaria in Africa[J]. N Engl J Med, 2021, 385(13): 1163-1171. DOI: 10.1056/NEJMoa2101746.
    [17] Ashley EA, Phyo AP, Woodrow CJ. Malaria[J]. Lancet, 2018, 391(10130): 1608-1621. DOI: 10.1016/S0140-6736(18)30324-6.
    [18] Gefen-Halevi S, Belinson V, Manor U, et al. HRP2/3 mutation in recrudescent Plasmodium falciparum malaria case acquired in Ethiopia[J]. J Travel Med, 2021, 28(5): taaa196. DOI: 10.1093/jtm/taaa196.
    [19] Yin J, Yan H, Li M. Prompt and precise identification of various sources of infection in response to the prevention of malaria re-establishment in China[J]. Infect Dis Poverty, 2022, 11(1): 45. DOI: 10.1186/s40249-022-00968-y.
    [20] Dong Y, Liu SP, Deng Y, et al. Genetic polymorphism of histidine rich protein 2 in plasmodium falciparum isolates from different infection sources in Yunnan Province, China[J]. Malar J, 2019, 18(1): 446. DOI: 10.1186/s12936-019-3084-4.
    [21] 陈田木, 张少森, 周水森. 疟疾再传播风险评估方法与指标参数的研究进展[J]. 中国寄生虫学与寄生虫病杂志, 2017, 35(5): 489-494.

    Chen TM, Zhang SS, Zhou SS. Progress in research on risk assessment approach and parameters for malaria re-emergence[J]. Chin J Parasitol Parasit Dis, 2017, 35(5): 489-494.
    [22] 兰子尧, 李杨, 黄雨婷, 等. 输入性疟疾再传播风险评估指标体系的构建[J]. 中国血吸虫病防治杂志, 2022, 34(2): 163-171. DOI: 10.16250/j.32.1374.2022023.

    Lan ZY, Li Y, Huang YT, et al. Construction of risk assessment index system for re-transmission of imported malaria[J]. Chin J Schistosomiasis Control, 2022, 34(2): 163-171. DOI: 10.16250/j.32.1374.2022023.
    [23] Lei L, Richards JS, Li ZH, et al. A framework for assessing local transmission risk of imported malaria cases[J]. Infect Dis Poverty, 2019, 8(1): 43. DOI: 10.1186/s40249-019-0552-6.
    [24] 莫晓彤, 夏尚, 艾琳, 等. 在消除阶段我国疟疾风险评估指标体系研究[J]. 中国热带医学, 2021, 21(6): 505-511. DOI: 10.13604/j.cnki.46-1064/r.2021.06.02.

    Mo XT, Xia S, Ai L, et al. Study on a framework for risk assessment of imported malaria in China during malaria elimination[J]. China Trop Med, 2021, 21(6): 505-511. DOI: 10.13604/j.cnki.46-1064/r.2021.06.02.
    [25] 陈田木. 疟疾再传播风险评估指标体系及模型研究[D]. 北京: 中国疾病预防控制中心, 2018.

    Chen TM. Study on risk assessment index system and model of malaria re-transmission[D]. Beijing: Chinese Center for Diseases Control and Prevention, 2018.
  • 加载中
计量
  • 文章访问数:  22
  • HTML全文浏览量:  8
  • PDF下载量:  8
  • 被引次数: 0
出版历程
  • 收稿日期:  2022-07-29
  • 修回日期:  2022-10-24
  • 网络出版日期:  2024-02-05
  • 刊出日期:  2024-01-10

目录

    /

    返回文章
    返回